SPMS

News

Novartis’ Mayzent has been approved in Europe for adults with secondary progressive multiple sclerosis (SPMS) and active disease.

Oncology

At Reuters Pharma USA this week, Boehringer Ingelheim's Vicky Brown spoke with us about the company's recent approval for Hernexeos in NSCLC.

Sales & Marketing

As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.